| 1 |
32391926 | Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells. | 2022 Jan |
4 |
| 2 |
35121728 | PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. | 2022 Feb 4 |
2 |
| 3 |
35142429 | Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. | 2022 Feb |
1 |
| 4 |
35196602 | PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner. | 2022 May |
1 |
| 5 |
35478108 | Reinforcement of Sorafenib Anti-osteosarcoma Effect by Amentoflavone Is Associated With the Induction of Apoptosis and Inactivation of ERK/NF-κB. | 2022 May-Jun |
1 |
| 6 |
33553331 | miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. | 2021 Jan |
1 |
| 7 |
33628103 | LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2021 |
2 |
| 8 |
33674622 | The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. | 2021 Mar 5 |
1 |
| 9 |
33803354 | Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma. | 2021 Mar 9 |
1 |
| 10 |
33839325 | TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. | 2021 Aug 4 |
1 |
| 11 |
33948974 | Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review. | 2021 Jul |
2 |
| 12 |
34069373 | Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. | 2021 May 19 |
1 |
| 13 |
34377232 | Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. | 2021 |
3 |
| 14 |
31469916 | CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. | 2020 Apr |
1 |
| 15 |
32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 |
1 |
| 16 |
32187962 | A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells. | 2020 May |
1 |
| 17 |
32300243 | Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. | 2020 Dec |
4 |
| 18 |
32354204 | Hedgehog Signal Inhibitor GANT61 Inhibits the Malignant Behavior of Undifferentiated Hepatocellular Carcinoma Cells by Targeting Non-Canonical GLI Signaling. | 2020 Apr 28 |
1 |
| 19 |
32776632 | A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. | 2020 Dec |
1 |
| 20 |
33021963 | MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression. | 2020 Sep 21 |
1 |
| 21 |
33209885 | Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression. | 2020 Oct |
2 |
| 22 |
30456603 | The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. | 2019 Oct |
3 |
| 23 |
30655811 | Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A. | 2019 Jan |
3 |
| 24 |
30761258 | Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. | 2019 Feb |
2 |
| 25 |
31233204 | Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway. | 2019 Sep |
3 |
| 26 |
29156516 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. | 2018 Jan |
4 |
| 27 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
4 |
| 28 |
29423069 | Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. | 2018 Jan 9 |
1 |
| 29 |
29538717 | Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. | 2018 May 3 |
4 |
| 30 |
29552199 | Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells. | 2018 Apr |
2 |
| 31 |
29573266 | Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. | 2018 Jul |
1 |
| 32 |
29702736 | Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. | 2018 Jul |
2 |
| 33 |
29782854 | Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. | 2018 Aug 5 |
1 |
| 34 |
29858683 | Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. | 2018 Aug |
5 |
| 35 |
30030148 | Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. | 2018 Nov |
6 |
| 36 |
30106087 | Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. | 2018 Nov |
2 |
| 37 |
30126548 | Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase 1/2 Activation. | 2018 Sep |
1 |
| 38 |
30426981 | Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. | 2018 Dec 3 |
1 |
| 39 |
27807662 | C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. | 2017 Feb |
2 |
| 40 |
27840968 | Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. | 2017 Jan |
5 |
| 41 |
28035421 | Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration. | 2017 Feb |
2 |
| 42 |
28161506 | Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. | 2017 Apr 28 |
5 |
| 43 |
28164434 | Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2017 Mar |
4 |
| 44 |
28260092 | Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. | 2017 Apr |
1 |
| 45 |
28276530 | Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. | 2017 Mar 9 |
2 |
| 46 |
28687354 | Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. | 2017 Oct 10 |
1 |
| 47 |
28693200 | Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells. | 2017 Jul |
2 |
| 48 |
28808038 | The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. | 2017 Nov 1 |
1 |
| 49 |
29030911 | Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. | 2017 Dec |
1 |
| 50 |
29113345 | Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. | 2017 Oct 6 |
3 |